Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

PEC Encap

Drug Profile

PEC Encap

Alternative Names: Allogeneic stem cell therapy - ViaCyte; Encapsulated human islet cell therapy - ViaCyte; Encapsulated islet cell transplantation therapy - ViaCyte; Encapsulated pancreatic cell transplantation therapy - ViaCyte; PEC-EnCap; PEC-Encap™; Pro-Islet; VC-01

Latest Information Update: 05 Dec 2018

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator ViaCyte Inc
  • Class Stem cell therapies
  • Mechanism of Action Pancreatic beta cell replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I/II Type 1 diabetes mellitus
  • Preclinical Type 2 diabetes mellitus

Most Recent Events

  • 29 Nov 2018 ViaCyte halts enrolment in the phase I/II STEP ONE trial in Type 1 diabetes mellitus citing product improvement reasons (with W. L. Gore and Associates)
  • 23 Jun 2018 Adverse events and efficacy data from phase I/II STEP ONE trial in Type-1 diabetes mellitus released by ViaCyte
  • 17 Apr 2018 Viacyte has patent protection for Stem Cell-Derived Cell Replacement Therapies in Europe, USA, Japan, China, Hong Kong, Singapore, South Korea and Australia
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top